+351 211 369 829 INFO@OPHIOMICS.COM

HepatoPredict first clinical validation published in Annals of Surgery

Our paper “A gene expression signature to select hepatocellular carcinoma patients for liver transplantation” is finally out and can be found here.

This study published in Annals of Surgery is the first clinical validation of HepatoPredict, an algorithm combining biomarkers measured in liver tumor with clinical variables, to predict recurrence after liver transplantation. 

In this collaborative retrospective study with Curry Cabral Hospital (Lisbon, Portugal) we showed that HepatoPredict reduces false negative rates and has positive predictive values (88,5%-94,4%). 

Overall, HepatoPredict outperforms conventional selection criteria such as Milan and UCSF, providing superior prognostic information. 

Share the Post:

Related Posts

Thinking Big!

Ophiomics is now participating in the IPOready program by Euronext. This is a great opportunity to consider the best strategy

Read More